

# DPP-4 inhibitors

Oral, weight-neutral diabetes drugs that block the enzyme that normally degrades the body's own incretin hormones - a modest-efficacy, low-hypoglycemia class whose main teaching point is that two of its four members carry a labelled heart-failure hospitalization signal that the other two do not.

Online guide: <https://www.medguideglobal.com/pharmacology/endocrine-and-metabolic/dpp4-inhibitors>

Content updated: 2026-09-15

## Quick revision

One Liner: DPP-4 inhibitors block the enzyme that degrades the body's own GLP-1 and GIP, giving a weight-neutral, low-hypoglycemia oral option with modest glucose-lowering power - and two of the four drugs, saxagliptin and alogliptin, carry a labelled heart-failure hospitalization signal that sitagliptin and linagliptin do not share in the same way.

1. DPP-4 inhibitors block the dipeptidyl peptidase-4 enzyme, which normally degrades endogenous GLP-1 and GIP, prolonging the action of the patient's own incretin hormones rather than supplying an external incretin analog. [1][5]
2. Because the mechanism amplifies the body's own glucose-dependent incretin signal, hypoglycemia risk on monotherapy is low, similar in logic to the GLP-1 receptor agonist class. [1]
3. The class is weight-neutral, unlike GLP-1 receptor agonists, and has the smallest average HbA1c reduction among the major glucose-lowering drug classes according to the ADA Standards of Care. [6]
4. Sitagliptin, linagliptin, saxagliptin and alogliptin are all once-daily oral tablets. [1][2][3][4]
5. Saxagliptin's SAVOR-TIMI 53 trial found more heart-failure hospitalizations with saxagliptin than placebo (3.5% versus 2.8%), and alogliptin's own label carries a similar heart-failure caution. [3][4]
6. Linagliptin is eliminated predominantly through the enterohepatic/biliary route rather than the kidney, so it needs no dose adjustment in renal impairment - a genuine pharmacokinetic outlier in this class. [2]
7. Acute pancreatitis and severe, disabling arthralgia (joint pain) are class-wide adverse effect signals described in each member's own labelling. [1][2][3][4]
8. None of the four DPP-4 inhibitors is appropriate for type 1 diabetes or diabetic ketoacidosis. [1][2]

## Overview

1. DPP-4 inhibitors, informally called gliptins, take a different route to the same incretin system that GLP-1 receptor agonists act on directly. Rather than supplying an external GLP-1 analog, they inhibit the dipeptidyl peptidase-4 enzyme responsible for rapidly degrading the body's own GLP-1 and GIP after release. Blocking that degradation step raises the concentration and prolongs the action of the patient's endogenous incretin hormones, which in turn increases glucose-dependent insulin secretion and reduces glucagon - the same downstream logic as the GLP-1 class, reached by amplifying the body's own signal instead of replacing it. [1][5]
2. That indirect mechanism produces a distinctive clinical profile: modest glucose-lowering efficacy, weight neutrality, and low hypoglycemia risk on monotherapy. The ADA Standards of Care in Diabetes explicitly ranks DPP-4 inhibitors as producing the smallest HbA1c reductions among the major glucose-lowering drug classes, in contrast to insulin, tirzepatide and select GLP-1 receptor agonists (particularly semaglutide), which produce the largest reductions. This modest efficacy, combined with a favourable tolerability profile, is why DPP-4 inhibitors are typically positioned as an add-on option rather than a first-line agent. [6]
3. The class's most important safety distinction runs between its members rather than across all four uniformly. Saxagliptin's dedicated cardiovascular outcomes trial, SAVOR-TIMI 53, found a higher rate of hospitalization for heart failure with saxagliptin than placebo (3.5% versus 2.8%), with the excess risk concentrated in patients who already had a prior history of heart failure or renal impairment. Alogliptin's own label carries a comparable caution about heart

failure risk. Sitagliptin and linagliptin do not carry the same labelled heart-failure hospitalization signal in the material reviewed here, which makes this a genuinely drug-specific rather than class-wide safety finding, similar in structure to the way the JAK-inhibitor boxed warning applies unevenly across that class. [3][4]

4. Pancreatitis and severe, disabling arthralgia are the two adverse-effect signals that do appear consistently across all four drugs' own labelling, alongside upper respiratory infection and nasopharyngitis as common, non-serious reactions. None of the four is indicated for type 1 diabetes or for treating diabetic ketoacidosis. [1][2][3][4]

## Classification and drug examples

Intro: All four are oral DPP-4 inhibitors sharing the same core mechanism; they are best distinguished by route of elimination and by which two carry the labelled heart-failure caution.

1. Name: Sitagliptin

1. Note: The first DPP-4 inhibitor approved in this class and the most widely prescribed.

Name: Sitagliptin

Januvia

Route: Oral, once daily

Note: No labelled heart-failure hospitalization signal in the material reviewed here; renal impairment requires dose reduction. [1] [1]

2. Name: Linagliptin

2. Note: The pharmacokinetic outlier of the class: eliminated predominantly through the enterohepatic/biliary route rather than the kidney.

Name: Linagliptin

Tradjenta

Route: Oral, once daily

Note: No dosage adjustment is recommended for renal impairment of any severity, unlike the other three members reviewed here. [2] [2]

3. Name: Saxagliptin

3. Note: The member with the dedicated cardiovascular outcomes trial that first identified the class's heart-failure hospitalization signal.

Name: Saxagliptin

Onglyza

Route: Oral, once daily

Note: SAVOR-TIMI 53 found more heart-failure hospitalizations with saxagliptin (3.5%) than placebo (2.8%). [3] [3]

4. Name: Alogliptin

4. Note: Carries a similar heart-failure caution to saxagliptin, plus a labelled hepatic-failure warning not emphasised to the same degree in the other three labels reviewed.

Name: Alogliptin

Nesina

Route: Oral, once daily

Note: Postmarketing reports of fatal and non-fatal hepatic failure are specifically described in alogliptin's own label. [4] [4]

## Mechanism of action

Summary: GLP-1 and GIP are incretin hormones released from the gut after a meal, and both are normally degraded within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 inhibitors block this enzyme, which raises the circulating concentration and extends the duration of action of the patient's own endogenous GLP-1 and GIP rather than supplying an external incretin analog. The prolonged incretin signal increases glucose-dependent insulin secretion from pancreatic beta cells and reduces glucagon secretion from alpha cells, lowering both fasting and postprandial

glucose.

Target: The dipeptidyl peptidase-4 (DPP-4) enzyme, which normally inactivates endogenous GLP-1 and GIP

Cidal Static: Not applicable - an enzyme-inhibition effect that raises the level of the patient's own hormone, not a cytotoxic or cytostatic one

Kill Kinetics: Glucose-lowering effect is present within the first dosing interval and requires continued dosing to be maintained

1. Step: 1

1. Title: A meal triggers release of endogenous GLP-1 and GIP

1. Detail: Intestinal L-cells and K-cells release these incretin hormones in response to nutrient absorption. [5]

2. Step: 2

2. Title: DPP-4 enzyme normally degrades these hormones within minutes

2. Detail: Without inhibition, native GLP-1 and GIP have a very short half-life because DPP-4 rapidly cleaves them. [5]

3. Step: 3

3. Title: The DPP-4 inhibitor blocks this degradation enzyme

3. Detail: Sitagliptin's label describes the drug as slowing the inactivation of incretin hormones, thereby increasing their bloodstream concentrations. [1]

4. Step: 4

4. Title: Elevated, longer-acting endogenous incretin levels increase glucose-dependent insulin secretion

4. Detail: The insulin-secretion effect remains glucose-dependent, which is the mechanistic reason hypoglycemia risk on monotherapy is low. [1][2]

5. Step: 5

5. Title: Elevated incretin levels also reduce glucagon secretion

5. Detail: Lower glucagon reduces hepatic glucose output, contributing to the overall glucose-lowering effect. [2]

## Major clinical uses

1. Drug: Sitagliptin

1. Organism: Not applicable

1. Indication: Type 2 diabetes mellitus

1. Line: adjunct to diet and exercise; commonly used as an add-on to metformin or other agents

1. Note: Not for type 1 diabetes or diabetic ketoacidosis. [1]

2. Drug: Linagliptin

2. Organism: Not applicable

2. Indication: Type 2 diabetes mellitus

2. Line: adjunct to diet and exercise

2. Note: No dosage adjustment needed for renal impairment of any severity, which makes it a practical choice in patients with reduced kidney function. [2]

3. Drug: Saxagliptin

3. Organism: Not applicable

3. Indication: Type 2 diabetes mellitus

3. Line: adjunct to diet and exercise

3. Note: Heart-failure risk factors are weighed before starting, given the SAVOR-TIMI 53 finding. [3]

4. Drug: Alogliptin

4. Organism: Not applicable

4. Indication: Type 2 diabetes mellitus

4. Line: adjunct to diet and exercise

4. Note: Recommended dose in normal or mildly impaired renal function is 25 mg once daily, with reductions specified for worse renal function in the full prescribing information. [4]

## Pharmacokinetics

### 1. Drug: Sitagliptin

1. Route: Oral tablet, once daily, with or without food

1. Absorption: Well absorbed orally

1. Csf Penetration: See prescribing reference

1. Metabolism: Minimal hepatic metabolism

1. Elimination: Primarily renal

1. Dose Adjust: Dose reduction required for moderate-to-severe renal impairment or end-stage renal disease requiring dialysis [1]

### 2. Drug: Linagliptin

2. Route: Oral tablet, once daily, with or without food

2. Absorption: Well absorbed orally

2. Csf Penetration: See prescribing reference

2. Metabolism: Largely unmetabolised

2. Elimination: Predominantly enterohepatic/biliary (about 80% of administered radioactivity) with a smaller renal component (about 5%)

2. Dose Adjust: No dosage adjustment recommended for renal impairment of any severity [2]

### 3. Drug: Saxagliptin

3. Route: Oral tablet, once daily

3. Absorption: Well absorbed orally

3. Csf Penetration: See prescribing reference

3. Metabolism: Hepatic, via CYP3A4/5, to an active metabolite

3. Elimination: Renal and hepatic

3. Dose Adjust: Renal impairment and concomitant strong CYP3A4/5 inhibitors [3]

### 4. Drug: Alogliptin

4. Route: Oral tablet, once daily

4. Absorption: Well absorbed orally

4. Csf Penetration: See prescribing reference

4. Metabolism: Minimal hepatic metabolism

4. Elimination: Primarily renal

4. Dose Adjust: Dose reduction required for renal impairment [4]

1. This page gives no dose regimens by design. Exact dosing, including renal-impairment adjustments, depends on the individual patient's kidney function and belongs in a current prescribing reference used by the treating clinician.

2. Linagliptin's enterohepatic elimination is the genuine pharmacokinetic outlier in this class - it is the only member of the four needing no renal dose adjustment, in contrast to sitagliptin, saxagliptin and alogliptin, which are all substantially renally cleared and require dose reduction as kidney function declines. [2][1][3][4]

3. Saxagliptin is the only member of the four with an active metabolite formed via hepatic CYP3A4/5 metabolism, which is also why concomitant strong CYP3A4/5 inhibitors are a specific dosing consideration for saxagliptin that does not apply the same way to the other three. [3]

## Adverse effects

### 1. Effect: Upper respiratory tract infection and nasopharyngitis

1. Detail: Among the most frequently reported adverse reactions ( 5% incidence) for sitagliptin, and a consistent finding across the class. [1]

### 2. Effect: Headache

2. Detail: Reported commonly with sitagliptin and consistent with the general tolerability profile of the class. [1]

3. Effect: Nasopharyngitis and headache with linagliptin

3. Detail: Consistent with the class-wide pattern of mild, non-serious upper respiratory and headache complaints. [2]

1. Effect: Acute pancreatitis

1. Detail: Postmarketing reports of acute pancreatitis, including fatal and hemorrhagic or necrotizing cases, have been described for sitagliptin, and pancreatitis warnings appear in linagliptin's, saxagliptin's and alogliptin's own labelling as well.

1. Action: Discontinue promptly if pancreatitis is suspected - persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting. [1][2][3][4]

2. Effect: Severe and disabling arthralgia (joint pain)

2. Detail: Described in linagliptin's and saxagliptin's labelling as a class-wide DPP-4 inhibitor phenomenon, with onset ranging from one day to years after starting treatment and symptom relief reported on discontinuation in some patients.

2. Action: Evaluate new or worsening joint pain during treatment; consider discontinuation if severe. [2][3]

3. Effect: Heart failure hospitalization (saxagliptin and alogliptin specifically)

3. Detail: SAVOR-TIMI 53 found more heart-failure hospitalizations with saxagliptin (3.5%) than placebo (2.8%); patients with pre-existing heart failure or renal impairment had a higher hospitalization rate regardless of treatment assignment. Alogliptin's label carries a comparable caution.

3. Action: Weigh heart-failure risk factors before starting saxagliptin or alogliptin; monitor for signs and symptoms of heart failure and consider discontinuation if it develops. [3][4]

4. Effect: Hypersensitivity reactions, including Stevens-Johnson syndrome

4. Detail: Sitagliptin's label describes serious hypersensitivity reactions, including anaphylaxis, angioedema and Stevens-Johnson syndrome, typically within the first three months of treatment.

4. Action: Discontinue and seek urgent care for signs of a serious allergic reaction. [1]

5. Effect: Hepatic failure (alogliptin specifically)

5. Detail: Postmarketing reports of fatal and non-fatal hepatic failure are described specifically in alogliptin's label.

5. Action: Monitor liver function and do not restart if liver injury is confirmed with no alternative explanation. [4]

6. Effect: Hypoglycemia in combination therapy

6. Detail: Low on monotherapy, but risk increases substantially when a DPP-4 inhibitor is combined with an insulin secretagogue such as a sulfonylurea, or with insulin.

6. Action: A lower dose of the concomitant secretagogue or insulin is often required. [1][2]

1. Drug: Sitagliptin

1. Effect: The only one of the four with Stevens-Johnson syndrome specifically named in the hypersensitivity warning in the labelling reviewed here. [1]

2. Drug: Linagliptin

2. Effect: The only member needing no renal dose adjustment at any severity, because of its predominantly enterohepatic elimination. [2]

3. Drug: Saxagliptin

3. Effect: The member with the dedicated large cardiovascular outcomes trial (SAVOR-TIMI 53) that identified the heart-failure hospitalization signal for this class. [3]

4. Drug: Alogliptin

4. Effect: The only one of the four with a specific postmarketing hepatic-failure warning in the labelling reviewed here. [4]

## Contraindications, precautions and interactions

History of a serious hypersensitivity reaction (e.g. anaphylaxis, angioedema, or a severe exfoliative skin condition) to the specific drug or its excipients - labelled for sitagliptin, linagliptin, saxagliptin and alogliptin. [1][2][3][4]

1. A personal history of pancreatitis warrants caution given the class-wide pancreatitis signal. [1]

2. Heart-failure risk factors, or an existing history of heart failure, are specifically weighed before starting saxagliptin or

alogliptin. [3][4]

3. Type 1 diabetes and diabetic ketoacidosis are not treated with this class; it is not appropriate or studied for that use. [1][2]

4. Severe or worsening joint pain during treatment is a reason to reassess continued use of any DPP-4 inhibitor. [2][3]

1. With: Insulin secretagogues (e.g. sulfonylureas) or insulin

1. Effect: Additive glucose-lowering effect raises hypoglycemia risk; a lower dose of the secretagogue or insulin may be needed. [1][2]

2. With: Strong CYP3A4/5 inhibitors

2. Effect: Specifically relevant to saxagliptin, which is metabolised via CYP3A4/5 to an active metabolite; dose adjustment may be needed. [3]

## Comparison tables

Title: Same mechanism, one drug-specific safety divide

Caption: All four are once-daily oral DPP-4 inhibitors, but they differ in elimination route and, most importantly for exam purposes, in whether they carry a labelled heart-failure hospitalization signal.

1. Key: drug

1. Label: Drug

2. Key: elimination

2. Label: Primary elimination route

3. Key: heart\_failure

3. Label: Heart-failure hospitalization signal

4. Key: distinguishing

4. Label: Distinguishing feature

1. Drug: Sitagliptin

1. Elimination: Renal

1. Heart Failure: Not labelled in the material reviewed

1. Distinguishing: First DPP-4 inhibitor approved; Stevens-Johnson syndrome named in hypersensitivity warning [1]

2. Drug: Linagliptin

2. Elimination: Enterohepatic/biliary

2. Heart Failure: Monitored as a general class caution but no dedicated outcomes-trial signal in the material reviewed

2. Distinguishing: No renal dose adjustment needed at any severity [2]

3. Drug: Saxagliptin

3. Elimination: Renal and hepatic (active metabolite via CYP3A4/5)

3. Heart Failure: Labelled: SAVOR-TIMI 53 found 3.5% vs 2.8% hospitalization for heart failure

3. Distinguishing: The drug with the dedicated cardiovascular outcomes trial for this finding [3]

4. Drug: Alogliptin

4. Elimination: Renal

4. Heart Failure: Labelled caution comparable to saxagliptin's

4. Distinguishing: Only member with a specific postmarketing hepatic-failure warning [4]

## High-yield exam pearls

1. Pearl: DPP-4 inhibitors amplify the body's own incretin hormones by blocking their degradation; GLP-1 receptor agonists supply an external incretin analog instead.

1. Why: This is the core mechanistic distinction between the two incretin-based classes and a frequent source of exam confusion. [1][5]

2. Pearl: The heart-failure hospitalization signal belongs specifically to saxagliptin (and, similarly, alogliptin) - not to sitagliptin or linagliptin in the material reviewed here.

2. Why: Treating the warning as class-wide rather than drug-specific is exactly the kind of overgeneralisation exam questions are designed to catch, echoing how the JAK-inhibitor boxed warning applies unevenly across that class. [3][4]
3. Pearl: Linagliptin is the DPP-4 inhibitor that needs no renal dose adjustment, because it is eliminated mainly through the enterohepatic/biliary route rather than the kidney.
3. Why: A frequently tested single-best-answer distinction: which gliptin is preferred in renal impairment. [2]
4. Pearl: DPP-4 inhibitors are weight-neutral, unlike the GLP-1 receptor agonists that share their incretin pathway.
4. Why: This is the practical reason the two mechanistically related classes are positioned so differently in clinical practice - one as a weight-management option, the other as a tolerability-first add-on. [6]
5. Pearl: The ADA Standards of Care rank DPP-4 inhibitors as having the smallest HbA1c-lowering effect among the major glucose-lowering classes.
5. Why: A commonly tested comparative-efficacy fact used to contrast this class against insulin, GLP-1 receptor agonists and tirzepatide. [6]

## Common exam traps

1. Trap: Assuming the heart-failure hospitalization warning applies equally to all four DPP-4 inhibitors.
1. Correction: It is a labelled finding specifically for saxagliptin (from its dedicated SAVOR-TIMI 53 outcomes trial) and alogliptin; sitagliptin and linagliptin do not carry the same signal in the material reviewed here. [3][4]
2. Trap: Confusing DPP-4 inhibitors with GLP-1 receptor agonists because both raise incretin activity.
2. Correction: DPP-4 inhibitors block the enzyme that degrades the patient's own GLP-1 and GIP; GLP-1 receptor agonists are injectable (or, for semaglutide, oral) analogs that activate the receptor directly and produce a much larger glucose-lowering and weight effect. [1][5]
3. Trap: Assuming DPP-4 inhibitors cause significant hypoglycemia on their own.
3. Correction: The glucose-dependent mechanism keeps monotherapy hypoglycemia risk low; risk rises specifically when combined with a sulfonylurea or insulin. [1][2]
4. Trap: Assuming every gliptin requires the same renal dose adjustment.
4. Correction: Sitagliptin, saxagliptin and alogliptin all require renal dose reduction as kidney function declines; linagliptin, eliminated predominantly through the enterohepatic route, needs no adjustment at any severity. [2][1][3][4]

## Self-test questions

1. Question: What is the core mechanistic difference between DPP-4 inhibitors and GLP-1 receptor agonists?
  1. DPP-4 inhibitors are injectable, GLP-1 receptor agonists are oral
  2. DPP-4 inhibitors block the enzyme that degrades the body's own incretins; GLP-1 receptor agonists directly activate the GLP-1 receptor with an external analog
  3. They have identical mechanisms with different names
  4. DPP-4 inhibitors cause more weight loss than GLP-1 receptor agonists
1. Explanation: DPP-4 inhibitors raise levels of the patient's own endogenous GLP-1 and GIP by blocking their degrading enzyme, while GLP-1 receptor agonists supply an external molecule that activates the GLP-1 receptor directly, producing a larger effect. [1][5]
2. Question: Which DPP-4 inhibitor has a dedicated cardiovascular outcomes trial (SAVOR-TIMI 53) showing a higher rate of heart-failure hospitalization than placebo?
  1. Sitagliptin
  2. Linagliptin
  3. Saxagliptin
  4. None of the class
2. Explanation: SAVOR-TIMI 53 studied saxagliptin specifically and found heart-failure hospitalization in 3.5% of the saxagliptin group versus 2.8% on placebo. [3]

3. Question: Which DPP-4 inhibitor requires no dose adjustment for renal impairment of any severity?

1. Sitagliptin
2. Alogliptin
3. Saxagliptin
4. Linagliptin

3. Explanation: Linagliptin is eliminated predominantly through the enterohepatic/biliary route, so no dosage adjustment is recommended for renal impairment at any severity, unlike the other three members of the class. [2]

4. Question: How does the DPP-4 inhibitor class compare with insulin and GLP-1 receptor agonists in HbA1c-lowering efficacy, per the ADA Standards of Care?

1. DPP-4 inhibitors produce the largest HbA1c reductions
2. DPP-4 inhibitors produce the smallest HbA1c reductions among major glucose-lowering classes
3. All classes produce identical HbA1c reductions
4. DPP-4 inhibitors cannot lower HbA1c at all

4. Explanation: The ADA Standards of Care describe insulin, select GLP-1 receptor agonists (particularly semaglutide) and tirzepatide as producing the largest HbA1c reductions, with DPP-4 inhibitors producing the smallest. [6]

5. Question: What joint-related adverse effect is described across DPP-4 inhibitor labelling?

1. Mild, self-limited myalgia only
2. Severe and disabling arthralgia, with onset from one day to years after starting treatment
3. Permanent joint destruction in all patients
4. No joint-related effects have been reported

5. Explanation: Linagliptin's and saxagliptin's labelling describe severe and disabling arthralgia as a recognised DPP-4 inhibitor class effect, with variable onset and symptom relief reported on discontinuation in some patients. [2][3]

6. Question: Which DPP-4 inhibitor's label specifically names Stevens-Johnson syndrome among its serious hypersensitivity reactions?

1. Linagliptin
2. Sitagliptin
3. Saxagliptin
4. Alogliptin

6. Explanation: Sitagliptin's label specifically names Stevens-Johnson syndrome, along with anaphylaxis and angioedema, among the serious hypersensitivity reactions that have occurred, typically within the first three months of treatment. [1]

## Frequently asked questions

1. Question: Why are DPP-4 inhibitors not used as first-line diabetes therapy as often as other classes?

1. Answer: They produce the smallest average HbA1c reduction among the major glucose-lowering drug classes according to the ADA Standards of Care, even though they are well tolerated, weight-neutral and carry a low hypoglycemia risk on their own. That combination positions them as a common add-on option rather than a first choice ahead of metformin or, increasingly, a GLP-1 receptor agonist. [6]

2. Question: Is the heart-failure warning the same for every DPP-4 inhibitor?

2. Answer: No. It is a labelled finding specifically tied to saxagliptin's own dedicated cardiovascular outcomes trial (SAVOR-TIMI 53) and to alogliptin's label; sitagliptin and linagliptin do not carry the same heart-failure hospitalization signal in the material reviewed here. Anyone starting saxagliptin or alogliptin with existing heart-failure risk factors should have that risk specifically discussed. [3][4]

3. Question: Can a DPP-4 inhibitor be used in someone with reduced kidney function?

3. Answer: Sitagliptin, saxagliptin and alogliptin all require a reduced dose as kidney function declines. Linagliptin is the exception: because it is eliminated mainly through the enterohepatic/biliary route rather than the kidney, no dosage adjustment is recommended for renal impairment of any severity. [2][1][3][4]

4. Question: Do DPP-4 inhibitors cause hypoglycemia?

4. Answer: Uncommonly on their own, because the mechanism amplifies glucose-dependent incretin signalling rather than driving insulin release regardless of glucose level. The risk rises meaningfully when a DPP-4 inhibitor is combined with a sulfonylurea or with insulin. [1][2]

## References

[1] JANUVIA (sitagliptin) tablets - prescribing information. DailyMed, U.S. National Library of Medicine .

<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=963792a9-4029-4e7b-9759-9ad52e1b0962>

[2] TRADJENTA (linagliptin) tablets - prescribing information. DailyMed, U.S. National Library of Medicine .

<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f>

[3] ONGLYZA (saxagliptin) tablets - prescribing information. DailyMed, U.S. National Library of Medicine .

<https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4f2a84f-5117-4738-b769-aba8debbddb0>

[4] NESINA (alogliptin) tablets - prescribing information. DailyMed, U.S. National Library of Medicine .

<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0>

[5] Dipeptidyl Peptidase IV (DPP IV) Inhibitors. StatPearls Publishing / NCBI Bookshelf 2023.

<https://www.ncbi.nlm.nih.gov/books/NBK542331/>

[6] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. American Diabetes Association, Diabetes Care 2026.

[https://diabetesjournals.org/care/article/49/Supplement\\_1/S183/163934/9-Pharmacologic-Approaches-to-Glycemic-Treatment](https://diabetesjournals.org/care/article/49/Supplement_1/S183/163934/9-Pharmacologic-Approaches-to-Glycemic-Treatment)

**For education only. This guide does not replace professional medical advice. Do not use it to choose or change treatment.**